Method for verifying enveloped virus resisting effect of traditional Chinese medicine compound in vitro and application

Through in vitro verification methods, combined with bioinformatics and molecular technology, the antiviral effect and mechanism of Chinese medicine compound prescriptions on coronavirus was verified, and the problem of unclear action mechanism of Chinese medicine compound prescriptions was solved, and the rapid and safe antiviral effect verification of Chinese medicine compound prescriptions was achieved.

CN118932008AInactive Publication Date: 2024-11-12CHENGDU MEDICAL COLLEGE +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411389445.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-08
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The mechanism of action of Chinese medicine compound prescriptions in anti-coronavirus is not clear. Most of the existing studies are in the stage of bioinformatics analysis and lack rapid and safe in vitro verification methods.

Method used

Methods to verify the anti-envelope virus effects of Chinese medicine compound prescriptions in vitro, including plasmid construction, pseudovirus construction, Chinese medicine compound prescription configuration, cytotoxicity detection, network pharmacological analysis and molecular docking virtual analysis, and verify Chinese medicine through fluorescence microscopy, fluorescence quantitative PCR and other technologies. Antiviral effects and mechanism of compound recipes.

Benefits of technology

This method is convenient and efficient, and can safely verify the anti-inflammatory and antiviral effects of Chinese medicine compound in a secondary biosafety laboratory, systematically explore the inhibitory effect and mechanism of Chinese medicine compound on the novel coronavirus, and is suitable for the inhibitory effect of other compound prescriptions. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932008A_ABST
    Figure CN118932008A_ABST
Patent Text Reader

Abstract

The invention discloses a method for in-vitro verification of enveloped virus resistance of a traditional Chinese medicine compound and application, belongs to the technical field of biological medicine, solves the problem that an antiviral action mechanism of the traditional Chinese medicine compound is not clear yet, and comprises the steps of plasmid construction, pseudovirus construction, traditional Chinese medicine compound preparation and detection of cytotoxicity of the traditional Chinese medicine compound through a CCK-8 method. Determining safety action time and concentration; through an infection inhibition experiment, the pseudovirus and the compound traditional Chinese medicine are co-cultured respectively, and the influence of the compound traditional Chinese medicine on virus infection activity is determined by observing the number of green fluorescent cells through a fluorescence microscope; a traditional Chinese medicine compound enveloped virus resisting mechanism is explored through a network pharmacology analysis and molecular docking virtual analysis method. According to the invention, a new coronavirus pseudovirus construction mode is adopted, and a signal analysis method and an in-vitro experiment verification method are combined, so that the inhibition effect and mechanism of a traditional Chinese medicine compound on the new coronavirus can be systematically explored.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a method for in vitro verification of the anti-enveloped virus effect of a traditional Chinese medicine compound and its application. Background Art

[0002] Envelope viruses often cause more serious infections in clinical practice because they contain capsid proteins. On the one hand, the envelope proteins of the virus can stimulate cellular immune responses as antigens. On the other hand, the envelope can help the virus enter cells and promote the fusion of cell and virus membranes. Influenza viruses, coronaviruses, and human herpes viruses that cause pandemics and severe symptoms in the population are all enveloped viruses. After invading cells, these viruses often cause immune disorders, oxidative stress, and a series of inflammation-related cascade reactions.

[0003] Coronavirus (CoV) refers to a single-stranded RNA positive-strand virus with an envelope and a spike protein. It has four structural proteins: surface spike protein (Pro S), envelope protein (Pro E), membrane protein (Pro M) and nucleocapsid protein (Pro N). There are currently four genera of coronaviruses, namely α-coronavirus (α-CoV), β-coronavirus (β-CoV), γ-coronavirus (γ-CoV) and δ-coronavirus (δ-CoV). Coronaviruses are widely spread in many vertebrates. Among them, mammals are the natural hosts of the α-CoV family and β-CoV, while γ-CoV and δ-CoV mainly infect poultry and birds. Alpha-CoV-1, Swine Acute Diarrhea Syndrome Coronavirus (SADS-CoV), Canine Corona Virus (CCoV) and Feline Infectious Peritonitis (FCoV) are all alpha-coronaviruses, which mainly manifest as diarrhea and respiratory infections; while beta-coronaviruses are an important source of severe respiratory diseases in humans. Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-COV and SARS-CoV-2 are all beta-coronaviruses, which have been shown to have the ability to infect multiple hosts and cause zoonotic diseases. This is closely related to the spike protein on the CoV virus membrane, and the receptors angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) were found to be the common invasion targets of these three coronaviruses. They are widely expressed in kidney cells, alveoli and lower respiratory tract cells of various mammals. Taking SARS-CoV-2 as an example, its Spike protein has two subunits, S1 and S2. There is a receptor binding domain (RBD) binding region on S1, which can recognize ACE2 on the cell membrane and bind to it more tightly. Taking SARS, MERS and SARS-CoV-2 as examples, coronaviruses have positive-strand RNA that is highly similar to mRNA structure. After invading cells, they can directly translate the virus's own RNA as a template and skip the reverse transcription process.Therefore, they not only develop rapidly, but also have a high recombination rate between RNA and RNA. Co-infection with multi-mutant viruses can increase the recombination rate and infectivity, making the Spike 89 protein highly variable (Denison et al, 2011). In addition, SARS-CoV-2 has also been found to invade the human body through multiple receptors, such as AXL (Wang et al, 2021), TMPRSS2 (Hoffmann et al, 2020), ACE2 (Lu et al, 2020) and NRP1 (Cantuti-Castelvetri et al, 92 2020). These characteristics usually lead to two consequences. First, after SARS-CoV-2 invasion, it is easy to quickly develop into a systemic disease in the human body and express in multiple organs. Second, vaccines, monoclonal antibodies and monomer drugs developed against multi-immunogens (such as Spike or other specific receptor proteins) are prone to failure. In addition, SARS-CoV-2 has a tendency to repeat infection and co-infection with other pathogens (Baddal et al, 97 2023). During the period of high incidence of influenza virus, mycoplasma and other viruses, SARS-CoV-2 co-infection is also a problem that needs to be solved urgently.

[0004] During the COVID-19 period, traditional Chinese medicine compound prescriptions such as Lianhua Qingwen Capsule (Qiao et al., 1002023), Compound XG-1 (SeyedAlinaghi et al., 2023), Qingfei Paidu Decoction (Wang et al., 2022b) played a huge role in clinical treatment, effectively curbing the spread of the epidemic and greatly reducing the mortality rate (Zhang et al., 2020). Since then, research results from many countries have successively shown that plants and their active ingredients have a positive inhibitory effect on COVID-19 (Shagufta & Ahmad, 2021). These effects are mainly reflected in two aspects, namely, the active ingredients of plants target and bind to SARS-CoV-2 proteins or 106 human receptors (Alkafaas et al., 2023) to inhibit viral invasion or inhibit key enzymes of viral replication and synthesis, such as Spike, ACE2, RdRp or Ppro (Palanisamy et al., 2022) and 3CLpro. On the other hand, important components of Chinese medicine and plants regulate immune-related pathways and inhibit cytokine storms. Compared with single drugs, Chinese herbal compound prescriptions can play a multi-target and multi-pathway role through reasonable compatibility. It has a good intervention effect on systemic diseases caused by COVID-19 and is widely used to treat mild and moderate patients. In addition, cocktail therapy and combination therapy (Wang et al., 2022a) have also shown better efficacy in the clinical treatment of COVID-19 patients, confirming the importance of multi-channel inhibition of COVID-19 infection. Among these Chinese herbal compound prescriptions against COVID-19, Huo Pu Xia Ling Tang and Gan Lu Jie Du San have been reported to have good antiviral and inflammatory effects. Clinical studies have shown that Gan Lu Xiao Du San combined with Western medicine has a cure rate of 100% for the treatment of COVID-19, high versatility, and no adverse reactions (Ling et al., 2020). It has also been reported that Gan Lu Xiao Du Tang can regulate the MAPK signaling pathway (Zuo et al., 2017). However, the antiviral mechanism of these Chinese herbal compound prescriptions is still unclear. Due to the complex mechanism of traditional Chinese medicine compound and the high biosafety level of coronavirus, the current research on traditional Chinese medicine compound anti-coronavirus is mostly in the bioinformatics analysis stage. Therefore, this study designed an experimental method to quickly and safely confirm the direct anti-coronavirus effect of traditional Chinese medicine compound in vitro and make a preliminary prediction of the mechanism. Summary of the invention

[0005] The present invention provides a method for in vitro verification of the anti-enveloped virus effect of a traditional Chinese medicine compound and its application, so as to solve the technical problem that the anti-viral action mechanism of the traditional Chinese medicine compound is still unclear.

[0006] To achieve the above object, the present invention provides the following technical solutions: The present application provides a method for in vitro verification of the anti-enveloped virus effect of a traditional Chinese medicine compound, which specifically comprises the following steps: S1. Plasmid construction: CMV-Fluc-EGFP plasmid was constructed in recipient cells using homologous recombination method; S2. Construction of pseudovirus: Using the three-plasmid system, construct pseudovirus with Fluc-EGFP dual reporter gene, and verify the infection ability and titer determination of pseudovirus through infection experiments; S3. Preparation of Chinese medicine compound: Dissolve the Chinese medicine compound in dimethyl sulfoxide and then dilute it, and prepare the medicine into different concentration gradients for later use; S4. Detect the cytotoxicity of the Chinese medicine compound by CCK-8 method to determine the safe action time and concentration; through infection inhibition experiment, co-culture the pseudovirus and the Chinese medicine compound, and observe the number of green fluorescent cells under fluorescence microscope to determine the effect of the Chinese medicine compound on the virus infection activity; S5. Explore the mechanism of the Chinese medicine compound against enveloped viruses through network pharmacology analysis and molecular docking virtual analysis methods, including exploring the key pathways and core target proteins of the compound on cells and the new coronavirus, and analyzing the potential targeting effects of the active ingredients in the compound; S6. Fluorescence quantitative PCR was used to verify the multi-target regulatory effect of the Chinese herbal compound against enveloped viruses, and to verify the targeted regulatory effect of the Chinese herbal compound on STAT3 / ACE2.

[0007] Furthermore, in step S1, the recipient cell is Escherichia coli Stbl3.

[0008] Further, in step S2, the formula for titer determination is: Titer (TU / ml) = ((F×N) / (D×V))×1000 F: Average percentage of fluorescent cells (wells with a transduction rate of 10% to 15% are usually selected); N: total number of cells in each well; D: virus dilution factor; V: volume of diluted virus added to each well (μl).

[0009] Furthermore, step S5 specifically includes the following sub-steps: S51. Determine the active ingredients of traditional Chinese medicine compound and their related disease targets using Herbs, TCMSP and Pubmed databases; S52. Obtain human protein-related information for all disease targets in the Uniport database, and screen disease targets associated with enveloped viruses from the Genecard database; S53, crossing the disease targets involved in the traditional Chinese medicine compound with the disease targets related to enveloped viruses to obtain a VENN diagram, and obtaining the targets of the traditional Chinese medicine compound for treating enveloped viruses; S54. Use String database and Cytoscape software to construct a PPI network, rank the targets of Chinese herbal compound for the treatment of enveloped viruses from high to low, and screen out the core targets; S55. Use David database to perform cross-gene Go enrichment analysis and KEGG pathway analysis to determine the signaling pathways involved in the treatment of enveloped viruses with traditional Chinese medicine compound; S56. Collect the crystal structures of target proteins ACE2 and Spike from the PDB database for homology modeling; S57, using AutodockVina software, intercalated natural small molecules, which are important components of traditional Chinese medicine compound; S58. Use Pymol software to analyze the results of molecular docking.

[0010] The present invention provides an application for in vitro verification of the anti-enveloped virus effect of a traditional Chinese medicine compound, which verifies the anti-SARS-CoV-2 virus effect of the traditional Chinese medicine compound.

[0011] Furthermore, the Chinese medicine compound includes 30g of honeysuckle, 30g of forsythia, 15g of schizonepeta, 15g of burdock fruit, 15g of mint, 30g of platycodon, 15g of apricot, 15g of patchouli, 15g of magnolia bark, 30g of poria, 15g of pinellia, 15g of cardamom, 30g of coix seed, 30g of white hyacinth bean, 30g of charred hawthorn, 15g of Jianqu, and 30g of reed root.

[0012] Furthermore, STAT3 is the core target of SARS-CoV-2 virus infection, and the Chinese medicine compound indirectly inhibits the expression of ACE2 by inhibiting the transcription of STAT3, thereby inhibiting the recognition and invasion of the viral membrane.

[0013] Beneficial effects achieved by the present invention: (1) The method and application of in vitro verification of the anti-enveloped virus effect of a Chinese herbal compound provided by the present invention is convenient, efficient, and safe, and can be carried out in a biosafety level 2 laboratory. By combining bioinformatics methods with molecular technology, the method can verify in vitro whether the Chinese herbal compound has the effect of directly inhibiting enveloped viruses, and can also preliminarily identify the active ingredients, potential targets and mechanisms of action of the Chinese herbal compound. The anti-inflammatory and antiviral effects of the Chinese herbal compound can be quickly and scientifically identified in vitro.

[0014] (2) The method and application of in vitro verification of the anti-enveloped virus effect of traditional Chinese medicine compound provided by the present invention establishes a systematic method for screening anti-coronavirus traditional Chinese medicine compound, and takes the lead in combining bioinformatics analysis methods with in vitro experimental verification methods by constructing a pseudovirus of the new coronavirus, systematically exploring the inhibitory effect and mechanism of traditional Chinese medicine compound on the new coronavirus. This method is also applicable to exploring the inhibitory effect of other compounds on coronavirus and other enveloped viruses.

[0015] (3) The method and application of in vitro verification of the anti-enveloped virus effect of traditional Chinese medicine compound provided by the present invention, the network pharmacology method can effectively correspond to the multi-target and multi-pathway regulation characteristics of traditional Chinese medicine compound preparations. This study integrates information from multiple databases to screen out the important ingredients in traditional Chinese medicine compound. In addition, by combining a variety of bioinformatics analysis methods, target screening is carried out from multiple signal pathways such as virus invasion, inflammation-related, and immune regulation, and the interaction between targeted viral proteins and targeted human receptor proteins is considered to more scientifically predict the potential mechanism of multi-target regulation of virus invasion by compound preparations.

[0016] (4) The present invention provides a method and application for in vitro verification of the anti-enveloped virus effect of a traditional Chinese medicine compound, which uses a pseudovirus system combined with an in vitro cell experiment to verify the direct antiviral effect of the Sichuan prescription preparation, uses network pharmacology and molecular docking methods to predict targets and pathways, and uses qPCR, gene knockout and other means to verify targets and explore mechanisms, thereby increasing the reliability of experimental results. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 It is the colony PCR diagram of the plasmid pCMV-Fluc-EGFP of the present invention; M represents the DNA standard marker, and 1, 2, 3, and 4 represent the colony PCR of the strain transformed with the pCMV-Fluc-EGFP plasmid respectively; Figure 2 The images are 10 times magnified images of cells infected by the present invention under blue excitation light in an inverted microscope; wherein a represents cells infected by VSV-G, b represents cells infected by SARS-CoV-2 (WT), and c represents cells infected by SARS-CoV-2 (Omicron); Figure 3 This is a protein blot analysis diagram of the present invention; M represents protein marker, O represents novel coronavirus pseudovirus (Omicron), S represents novel coronavirus pseudovirus (WT), and V represents VSV-G pseudovirus; Figure 4 It is a line graph of the inhibition rate of cells by the four traditional Chinese medicine compound prescriptions of the present invention at 12 hours; Figure 5 It is a line graph of the inhibition rate of the four traditional Chinese medicine compounds of the present invention on cells in 24 hours; Figure 6It is a line graph of the inhibition rate of the four traditional Chinese medicine compounds of the present invention on cells at 48 hours; Figure 7 It is a line graph of the inhibition rate of the four traditional Chinese medicine compounds of the present invention on cells at 72 hours; Figure 8 This is the result of the Chinese medicine compound No. 1 of the present invention inhibiting virus invasion; Fig. 9 This is the result of the Chinese medicine compound No. 2 of the present invention inhibiting virus invasion; Fig.10 This is the result of the Chinese medicine compound No. 3 of the present invention inhibiting virus invasion; Fig.11 This is the result of Lianhua Qingwen Capsule in the present invention inhibiting virus invasion; Fig.12 A Venn diagram mapping the disease targets involved in the four traditional Chinese medicine compound prescriptions of the present invention to the targets related to novel coronavirus infection; Fig.13 This is the KEGG enrichment result diagram of the present invention; Fig.14 This is a graph showing the results of GO enrichment analysis of the present invention; Fig.15 The docking results of STAT3 and ACE2 of the present invention are shown in Figure A, which shows the self-docking result of ACE2 and fortunellin in the compound; and Figure B shows the docking result of STAT3 protein and fortunellin; Fig.16 is a map of the CMV-Fluc-EGFP plasmid of the present invention; In the figure, LH represents Lianhua Qingwen Capsules, NO.1 represents Chinese herbal compound No. 1, NO.2 represents Chinese herbal compound No. 2, and NO.3 represents Chinese herbal compound No. 3.

[0018] The drawings are only used for illustrative purposes and should not be construed as limitations on this patent. In order to better illustrate this embodiment, some parts of the drawings may be omitted, enlarged or reduced, and do not represent the size of the actual product. For those skilled in the art, it is understandable that some well-known structures and their descriptions in the drawings may be omitted. The same or similar numbers correspond to the same or similar parts. The terms describing the positional relationship in the drawings are only used for illustrative purposes and should not be construed as limitations on this patent. DETAILED DESCRIPTION

[0019] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. In addition, the technical solutions between the various embodiments can be combined with each other, but they must be based on the ability of ordinary technicians in this field to implement them. When the combination of technical solutions is contradictory or cannot be implemented, it should be considered that such a combination of technical solutions does not exist and is not within the scope of protection required by the present invention.

[0020] The technical solution of the present invention is described in detail below in conjunction with the specific drawings.

[0021] 1. A method for in vitro verification of the anti-enveloped virus effect of a traditional Chinese medicine compound

[0022] Example 1: Preparation of materials The 293T cells used in this experiment were purchased from ATCC, fetal bovine serum was purchased from BioInd, DMEM high glucose medium was purchased from Gibico, trypsin and streptomycin-penicillin double antibody medium were purchased from Hyclone, rabbit polyclonal antibody secondary antibody, color development solution and RIPA protein extraction kit for western blotting were purchased from Sangon Biotech, rabbit polyclonal anti-S2 primary antibody was purchased from AB Cloning Antibody, protein marker was purchased from Bausde, plasmids psPAX2, PMD2.G and ACE2 were purchased from Hewu Bio, plasmids Fluc, CMV-GFP were purchased from addGene, Spike (Omicron) was purchased from HonorGene, plasmid extraction kit was purchased from Tiangen, lipo8000 transfection agent and Fluc firefly luciferase detection kit were purchased from BeyotimeBiotechnology, CCK-8 toxicity test kit was purchased from Biosharp. ChamQ Universal SYBR qPCR Master Mix was purchased from Nanjing Novozyme Biotechnology Co., Ltd., and gDNA eraser was purchased from Takara.

[0023] Example 2: Plasmid construction Plasmids psPAX2, PMD2.G, CMV-ACE2, pLenti GFP, CMV-SRS-CoV2-Spike (Omicron), and SARS-CoV-2 Spike (WT) were transferred into E. coli recipient cells Stbl3 by chemical transfer. After oscillation for 12 to 16 hours, the cells were extracted using an endotoxin-free plasmid extraction kit. Fragment PCR and vector PCR were performed on plasmid Fluc and vector CMV-EGFP, respectively. After gel recovery, CMV-Fluc-EGFP was constructed by homologous recombination.

[0024] Example 3: Pseudovirus Construction Logarithmically growing 293T cells were cultured at 37°C and 5% CO2 for 24 h, with 5 × 10 cells per well of a 6-well plate. 5 cells. After 24 hours, the cells were replaced with liquid. One hour after the liquid exchange, the plasmids psPAX2, CMV-EGFP and PMD2.G were mixed with 750 ml of serum-free medium in a ratio of 9:9:3, and 38 μl of Lipo8000 was added. 125 μl of the mixture was added to each well. 36 hours after transfection, the supernatant was collected and replaced. After 72 hours, the supernatant was collected again. The supernatants collected twice were mixed and filtered with a 45 nm filter membrane. Virus concentration was performed by adding PEG8000 in a ratio of 1 to 0.25. Reverse stirring 3 times every 15 minutes, let stand overnight, and centrifuge in an 8000 rpm centrifuge. The virus concentrate was stored at -80°C.

[0025] Example 4: Virus titration assay 293T cells were arranged in a 96-well plate, with 2×10,000 cells in each well. The obtained virus concentrate was diluted in 5 gradients according to the 10-fold gradient dilution method. After 24 hours of cell culture, 100 μl of virus gradient dilution solution was added, and 3 replicates were set for each concentration. After 72 hours of continuous culture, the fluorescence number of each well was observed under an inverted microscope. The number of fluorescent points represents the virus titer, and the virus titer is calculated according to the formula.

[0026] The expression of EGFP is used to indicate the titer of pseudoviruses. Each bright fluorescent spot is counted as 1 titer. The titer of the synthetic SARS-CoV-2 pseudovirus is calculated by the following formula. The series of results show that when diluted 10 times, the titers of the constructed SARS-CoV-2 PV (Omicron), SARS-CoV-2 PV (WT) and VSV-G are all about 10 8 .

[0027] Titer (TU / ml) = ((F×N) / (D×V))×1000 F: Average percentage of fluorescent cells (wells with a transduction rate of 10% to 15% are usually selected); N: total number of cells in each well; D: virus dilution factor; V: volume of diluted virus added to each well (μl).

[0028] Example 5: Immunoblotting 293T cell line was seeded in 6-well plates. After 6 hours of culture, the liquid was changed and Omicron, Spike and VSVG pseudovirus were added according to MOI = 1. After 72 hours of culture, the green fluorescence was bright. Then, the medium was aspirated and the cells were lysed with RIPA cell lysate. The cells were sticky, mixed by inversion on ice, centrifuged, and the supernatant was aspirated. The protein concentration was determined by a spectrophotometer. After dilution to 80ng / ml, the protein was inactivated by heating at 95℃ for 1min. 6% stacking gel and 5% separation gel were configured, concentrated at 80V15min, and then run for 40min. Then, 120A constant flow membrane for 3 hours. The remaining protein gel was stained with Coomassie brilliant blue and destained to check whether there was no residual protein. After closing the membrane, the primary anti-S2 rabbit polyclonal antibody was incubated overnight at 4℃, and the secondary anti-polyclonal antibody was incubated for 1h. Color exposure was performed by chemiluminescence imager.

[0029] Example 6: Preparation of Chinese medicine compound Chinese medicine compound No. 1 (NO.1): contains 15g of white cardamom seed, 30g of patchouli, 30g of capillaris, 30g of chuanmutong, 30g of calamus, 15g of scutellaria, 30g of forsythia, 30g of thunbergii, 30g of belamcanda 30g, and 15g of mint. The mixing reagent is first dissolved with dimethyl sulfoxide (DMSO), and then diluted twice with 10 times in a continuous gradient to prepare a 200mg / ml stock solution. It is then diluted twice with cell culture medium in a continuous gradient, and then diluted according to the proportion to prepare the agent into a concentration gradient of 2, 1.5, 1, 0.5, and 0.1mg / ml.

[0030] Chinese medicine compound No. 2 (NO.2): contains 30g of honeysuckle, 30g of forsythia, 15g of schizonepeta, 15g of burdock, 15g of mint, 30g of platycodon, 15g of apricot, 15g of patchouli, 15g of magnolia bark, 30g of tuckahoe, 15g of pinellia tuber, 15g of cardamom, 30g of coix seed, 30g of white lentil, 30g of charred hawthorn, 15g of Jianqu, and 30g of reed root, all of which are standardized Chinese medicine granules produced using infrared fingerprint technology. After dissolving with DMSO, dilute twice to make a mother solution of 490mg / ml, and then dilute twice with cell culture medium in a continuous gradient, and then dilute according to the proportion to make the agent into a concentration gradient of 2, 1.5, 1, 0.5, and 0.1mg / ml.

[0031] Chinese medicine compound No. 3 (NO.3): contains 15g of schizonepeta, 15g of siler, 15g of chuanxiong, 15g of angelica, 15g of mint, 30g of platycodon, 15g of patchouli, 15g of perilla leaf, 15g of magnolia bark, 30g of stir-fried atractylodes, 15g of fennel, 15g of jianqu, 30g of huiyiren, 30g of tuckahoe, 15g of cardamom, 15g of almond, 30g of charred hawthorn, 30g of white lentil, and 30g of reed root, all of which are standardized Chinese medicine granules produced using infrared fingerprint technology. After the compound granules are dissolved in DMSO, they are diluted twice to prepare a 590mg / ml mother liquor, and then diluted twice in a continuous gradient with cell culture medium, and then diluted according to the proportion to prepare the agent into a concentration gradient of 2, 1.5, 1, 0.5, and 0.1mg / ml.

[0032] Lianhua Qingwen Capsules were diluted with DMSO to prepare a stock solution of 35 mg / ml, and then diluted once more to prepare a concentration gradient of 1.5, 1, 0.5, and 0.1 mg / ml.

[0033] Example 7: Toxicity test of the compound on 293T cells The Chinese medicinal materials of Chinese medicinal compound No. 1 were purchased from Green Pharmaceutical Biotechnology Co., Ltd., and the Chinese medicinal materials of Chinese medicinal compound No. 2 and No. 3 were purchased from Beijing Kangrentang Pharmaceutical Co., Ltd. Chinese medicinal compound No. 1, Chinese medicinal compound No. 2, and Chinese medicinal compound No. 3 were all prepared by themselves, and Lianhua Qingwen Capsule (YBZ03752004-2009Z) was from Yiling Pharmaceutical. These compound preparations were dissolved in DMSO respectively. According to the gradient dilution method, they were configured to 2, 1.5, 1.0, 0.5, and 0.1 mg / ml. The DMSO content in the final concentration was less than 10%. 293T cells in the logarithmic growth phase were placed on 96-well plates and overgrown by 70% after 24 hours. The drug was treated with 3 wells at each concentration, and the experiment was repeated 3 times. After 12, 24, 48, and 72 hours, the medium was changed and washed twice with PBS, and 10 μl of CCK-8 detection reagent was added to each well. After 2 hours, the activity of cells was detected by enzyme labeling at an excitation wavelength of 450 nm.

[0034] Example 8: Virus invasion inhibition rate 293T cells were seeded in 96-well plates. When the overgrowth was 70% after 24 hours, the liquid was changed and four Chinese herbal compound prescriptions were added at 2, 1.5, 1, 0.5 and 0.1 mg / ml. After 1 hour of treatment, 10 μl of pseudovirus with a titer of 100,000 was added to each well. VSV-G with high EGFP expression was used as a negative control group. The experimental groups were Omicron and Spike with high EGFP expression. Lianhua Qingwen was used as a positive control group and the experiment was repeated 3 times. After 72 hours of incubation, the number of EGFP fluorescence in each well was counted, and the inhibitory effect of the pseudovirus was calculated. The cells were placed on a 48-well plate, and 2×10,000 cells were inserted into each well. After 24 hours, four compound prescriptions with final concentrations of 2, 1.5, 1, 0.5 and 0.1 mg / ml were added. Pseudovirus with high Fluc-EGFP expression was introduced into the cells according to MOI=1. After 72 hours of culture, the medium was aspirated and washed twice with PBS, 40 μl of cell lysate was added to each well for cutting, centrifuged at 12000 for 4 minutes, the supernatant was aspirated, 96 black plates were added, and substrate was added for 1 minute. Enzyme activity was determined by chemiluminescent enzyme labeling.

[0035] Example 9: qPCR Three experimental groups were set up: a positive control group, a control group without Omicron, and a blank control group with only cells. The concentrations of Lianhua Qingwen Capsule, Chinese Medicine Compound No. 1, Chinese Medicine Compound No. 2, and Chinese Medicine Compound No. 3 were 500, 500, 250, and 750 μg / ml, respectively, and the virus MOI = 1. After a total of 48 hours, the culture medium was removed, washed twice with cold PBS, and 500 μl of Trizol was added to each well. After 15 minutes of reaction, the culture medium was transferred to a centrifuge tube, 100 μl of chloroform was added to each tube, and then vigorously mixed. After centrifugation, the supernatant was absorbed and 1.5 times the volume of isopropanol was added. After standing for 2 hours, 75% ethanol was added to the precipitate twice. 80 μl of cDNA was obtained by TAKARA reverse transcription kit. 20 μl qPCR reaction solution was prepared, i.e., 0.4 μl positive and negative primers. The primer sequences were obtained by literature search or NCBI Primer-BLAST and verified by Primer-BLAST. All primers were synthesized by Shanghai Bio-Engineering Company and qPCR was performed using CFX96 fluorescent PCR instrument (Bio-Rad Company). The primer-related information and qPCR reaction system are shown in Tables 1 and 2 below.

[0036] Table 1 Primer related information Gene (upstream F / downstream R) serial number Sequence (5'→3') GAPDH-F SEQ ID NO.1 ACAACTTTGGTATCGTGGAAGG GAPDH-R SEQ ID NO.2 GCCATCACGCCACAGTTTC hACE2-F SEQ ID NO.3 CGAGTGGCTAATTTGAAACCAAGAA hACE2-R SEQ ID NO.4 ATTGATACGGCTCCGGGACA IL6-F SEQ ID NO.5 GGTACATCCTCGACGGCATCT IL6-R SEQ ID NO.6 GTGCCTCTTTGCTGCTTTCAC TNFα-F SEQ ID NO.7 CTGCCCCAATCCCTTTATT TNFα-R SEQ ID NO.8 CCCAATTCTCTTTTTGAGCC NFκB1-F SEQ ID NO.9 GAAGCACGAATGACAGAGGC NFκB1-R SEQ ID NO.10 GCTTGGCGGATTAGCTCTTTT IKKα-F SEQ ID NO.11 GGCTTCGGGAACGTCTGTC IKKα-R SEQ ID NO.12 TTTGGTACTTAGCTCTAGGCGA STAT3-F SEQ ID NO.13 CAGCAGCTTGACACACGGTA STAT3-R SEQ ID NO.14 AAACACCAAAGTGGCATGTGA IκBA-F SEQ ID NO.15 ACCTGGTGTCACTCCTGTTGA IκBA-R SEQ ID NO.16 CTGCTGCTGTATCCGGGTG Akt1-F SEQ ID NO.17 TCCTCCTCAAGAATGATGGCA Akt1-R SEQ ID NO.18 GTGCGTTCGATGACAGTGGT NLPR3-F SEQ ID NO.19 AGCCACGCTAATGATCGACT NLPR3-R SEQ ID NO.20 AACCCATCCACTCCTCTTCA JAK1-F SEQ ID NO.21 CTTTGCCCTGTATGACGAGAAC JAK1-R SEQ ID NO.22 ACCTCATCCGGTAGTGGAGC Table 2 qPCR system Reagents dose The reaction solution in the previous step 10 μl PrimeScript RT Enzyme Mix Ⅰ 1.0 μl RT PrimeScript Mix 1.0 μl 5×PrimeScript Buffer 2 4.0 μl <![CDATA[RNase Free dH2O]]> 4.0 μl Total 20 μl Example 10: Network pharmacology analysis and molecular construction The active ingredients in the four compounds and their related disease targets were obtained from the databases of Herbs, TCMSP, and Pubmed. In addition, the important active ingredients in the four compounds were screened out by OB ≥ 30% and DL 0.18. In the Uniport database, human protein-related information of all disease targets was obtained. Then, more than 17,000 disease targets related to SARS-CoV-2 were screened from the Genecard database. The disease targets involved in the compound were crossed with the targets related to SARS-CoV-2 to obtain the VENN diagram. The PPI network was constructed using the String database and Cytoscape software. Go enrichment analysis and KEGG pathway analysis of crossed genes were performed using the David database. The crystal structures of the target proteins ACE2 and Spike were collected from the PDB database for homology modeling. The natural small molecules (a total of 418) that were the important components of the four compounds were intercalated using the AutodockVina software. When the binding energy is less than 8.0, it is generally considered to have a potential targeting effect. The results of molecular docking were analyzed using the Pymol software.

[0037] All data were processed using GraphPad Prism 3.0 software. Except for the determination of EC50 and specificity analysis of the compound anti-SARS-CoV-2 (OMICRON) using the t-test method, all other data were analyzed using one-way ANOVA and two-way ANOVA. The error bars are represented as mean ± SD (n = 3), and the top and bottom of the error bars represent the maximum and minimum values ​​of the data, respectively. P values ​​less than 0.05 are considered to be significantly different.

[0038] 2. Results 2.1 Construction of SARS-CoV-2 pseudovirus 2.1.1 SARS-CoV-2 and VSV-G pseudovirus results Using homologous recombination method, CMV-Fluc-EGFP plasmid was successfully constructed in recipient cells Escherichia coli Stbl3. Figure 1 As shown in Figure 2, the agarose gel electrophoresis results after colony PCR showed a bright band of about 3000 bp, which was consistent with expectations. The sequencing results also showed that the plasmid CMV-Fluc-EGFP was successfully constructed. Fig.16As shown. The SARS-CoV-2 pseudovirus was constructed by transfecting 293T cells with a three-plasmid system at a ratio of 9:9:3. After 1 day, green fluorescence was observed in the SARS-CoV-2 (WT) group, the SARS-CoV-2 (Omicron) group, and the negative control VSV-G group. The collected supernatant was filtered and concentrated to infect 293T cells. After 3 days, the expression of EGFP fluorescent protein was observed under a 10x microscope, as shown Figure 2 As shown, a in the figure indicates that 3 days later, 10 times diluted, VSV-G infected cells were magnified 10 times under blue excitation light in an inverted microscope; b indicates that 3 days later, 10 times diluted, under an inverted microscope, magnified 10 times, SARS-CoV-2 (WT) infected cells; c indicates that 3 days later, 10 times diluted, under an inverted microscope, 10 times magnified, SARS-CoV-2 (Omicron) infected cells. The pseudovirus successfully fused with the cell membrane, the pseudovirus entered the cell to express the gene, and the SARS-CoV-2 and VSV-G pseudoviruses were successfully constructed.

[0039] 2.1.2 Western blot analysis of pseudovirus construction results In the process of the spike protein of the SARS-CoV-2 pseudovirus recognizing the cell ACE2 receptor and producing membrane fusion, the spike protein will be sheared and the S2 subunit will enter the cell through endocytosis. Western blot analysis was performed using Spike-S2 rabbit polyclonal antibody as the first antibody. The results are as follows Figure 3 As shown, at MOI = 1, S2 rabbit polyclonal antibody was used as the secondary antibody, and total proteins extracted from SARS-CoV-2PV (Omicron), SARS-CoV-2PV (WT) and VSV-G were used for Western blot analysis; the results showed that the blots of SARS-CoV-2 (Omicron) and SARS-CoV-2 (WT type) were approximately 65 kDa, and there was no VSV-G band in the negative control group.

[0040] 2.2 Four Chinese herbal medicines inhibit viral invasion in vitro 2.2.1 Toxicity test of Chinese herbal medicine on 293T cells The concentration gradients of the four compounds were set at 2, 1.5, 1, 0.5 and 0.1 mg / ml, and the OD values ​​of 293T cells in 96-well plates were measured at a wavelength of 450 nm by CCK-8 method after incubation for 12, 24, 48 and 72 hours, respectively. Figure 4-Figure 7As shown in the figure, LH represents Lianhua Qingwen Capsule. At high concentrations, the cytotoxic effects of the four compound drugs increase over time. Among them, Compound 2 has a greater toxic effect on cells, and as time goes by, its metabolites may enhance the toxic effects of cells. At 72 hours, the inhibition rates of Chinese medicine compound 1, Chinese medicine compound 2, Chinese medicine compound 3 and Lianhua Qingwen Capsule at 1 mg / ml were 8.9%, 13%, 1.5% and 17%, respectively. According to the calculation of the therapeutic index SI=CC50 / EC50, it can be seen that the SI index of the four compound drugs is greater than 1, which is effective.

[0041] 2.2.2 Inhibitory effect of traditional Chinese medicine compound on SARS-CoV-2 pseudovirus membrane fusion The expression of fluorescent protein EGFP was observed under an inverted microscope. The decrease in virus titer in cells indicated that the compound had an inhibitory effect on the invasion of pseudovirus membrane fusion at different concentrations. Figure 8-Figure 11 As shown, 293T cells were infected with SARS-CoV-2, MOI = 0.1, VSV-G was used as the negative control group, MOI and medication conditions were the same, the virus inhibition rate was calculated by counting the EGFP fluorescence number and reflecting the virus titer after the drug action, and the inhibition rate curve was fitted using the formula Y = b + (ab) / (1 + 10^ (Logc-X)), Omicron conformed to the fitting inhibition curve with R> 0.95, while the negative control group did not follow this trend. The EC50 values ​​of Chinese medicine compound No. 1, No. 2, No. 3 and Lianhua Qingwen for pseudovirus infection were 0.92, 0.52, 1.88 and 1.30 mg / ml, respectively (t test or one-way ANoVA, P < 0.01, statistically significant). Under the same conditions (MOI = 0.1, the same Chinese medicine concentration gradient, the same treatment time), WT SARS-CoV-2 PV was also used for experiments. These four compounds also have a direct inhibitory effect on the invasion of WT severe acute respiratory syndrome coronavirus 2. However, at the same concentration, compound 1 and compound 3 were less effective than Omicron.

[0042] 2.3 Network pharmacology analysis: KEGG, Go enrichment analysis, PPI network construction Through the databases Herbs, TCMSP and Pubmed, 1897, 1161, 1120 and 1383 active ingredients were collected from Chinese herbal compound 1, Chinese herbal compound 2, Chinese herbal compound 3 and Lianhua Qingwen, respectively. Compared with Lianhua Qingwen, there are 739 common active ingredients and 412 unique active ingredients in compound No. 2. The 649 active ingredients of compound No. 3 do not overlap with Lianhua Qingwen. Compound 1 has 1024 unique active ingredients. The active ingredients of the four compounds intersect. It can be found that in these compounds, some high-potential active ingredients work synergistically, such as quercetin, baicalin and β-sitosterol, indicating that these compounds can inhibit inflammation or regulate immunity through similar pathways. In addition to common ingredients, No. 1, No. 2, No. 3 and Lianhua Qingwen also have 747, 160, 208 and 241 unique active ingredients, respectively. Afterwards, a total of 14,607 disease targets related to SARS-CoV-2 were obtained by searching the GeneCards database. The compound disease targets retrieved from UNIPORT were mapped to disease targets related to SARS-CoV-2, and the Venn diagrams obtained were as follows: Fig.12 Among them, the disease targets involved in compound 1, 2, 3 and Lianhua Qingwen are 1140, 986, 1212, 1503, respectively, and the common target associated with SARS-CoV-2 is 352, which greatly indicates that these four compound prescriptions have multi-target and multi-pathway effects.

[0043] Go enrichment analysis and KEGG pathway analysis were performed using the DAVID database. The PPI network was drawn based on the string database and Cytoscape. The KEGG results in the figure are as follows Fig.13 As shown in the figure, among the 20 pathways with the best P values, three pathways are related to human viral infection, such as influenza A and human cytomegalovirus, and six pathways are related to immunity and inflammation. These cross-targets are also involved in multiple signaling pathways related to SARS-CoV-2 invasion, inflammation, and immunity, including TNF-α / IL17 signaling pathway, JAK signaling pathway, and Akt signaling pathway. The GO results of the three ontologies are shown in Figure 2. Fig.14As shown in the figure, the three ontologies are the molecular function (MF), cellular component (CC), and biological process (BP) of the gene. These common targets are involved in biological processes such as oxidation, metabolism, drug response, membrane fusion process, and cytokine / cytokine receptor binding reaction. In addition, after GO enrichment analysis of these cross-protein targets, we selected the top five pathways related to viral infection and drew a chord diagram. We found that some key protein targets, such as STAT3 (related to viral invasion), Akt1 (related to cell growth and metabolism), IL6, and TNF (related to inflammatory response), may be common targets of multiple viruses. In other words, they may be key targets for broad-spectrum antiviral therapy. Among these five viruses, ACE2 is the only target of SARS-CoV-2. In the PPI network construction results, it can also be observed that Akt1, TNF, JUN, IL6, and STAT3 are common targets of multiple pathways.

[0044] 2.4 Molecular docking and virtual screening to predict the targeted inhibitory effects of compound active ingredients In the TCMSP and PubChem databases, the small molecule 3D structures of the important active ingredients of the compound were collected and virtually screened using AutodockVina software. The docking boxes of the candidate proteins Spike and ACE2 crystals were determined by pyMol. Based on the binding energy greater than -8kJ / mol as the effective result, 22 small molecule natural products with good docking effects with the spike protein were finally screened out. 183 small molecules with low docking energy with ACE2 were screened out. Among the top 20 small molecules, most of them came from the compound Lianhua Qingwen, followed by compound No. 1, No. 2 and No. 3, indicating that Lianhua Qingwen and compound No. 1 may bind to the target protein Spike or ACE2 through a variety of potential small molecule drugs to inhibit the invasion of SARS-CoV-2.

[0045] In addition, the virtual docking results of ACE2 and STAT3 with the key active ingredients in the compound showed that Fortunellin is a more effective multi-target inhibitor. Fig.15 As shown, Fig.15 The results of the docking of small molecules Xambioona and Glycyrrhizin E with AutodockVina of ACE2 were shown, respectively. The results showed that these two small molecules are most likely to form stable bonds with ACE2 through hydrogen bonds.

[0046] The molecular docking results of four traditional Chinese medicine formulas were analyzed and heat maps were drawn. Taking the docking energy of -8kJ / mol as the critical point, 14, 12 and 8 molecules in compound NO.1, NO.2 and NO.3, respectively, could stably bind to the Spike target. There were 43, 49 and 43 small molecules that could target ACE2, accounting for 0.33, 0.42 and 0.36 of the important active small molecules in each compound, respectively. Compound NO.1, NO.2 and NO.3 had 44, 35 and 27 active small molecules that could stably bind to STAT3, accounting for 0.34, 0.30 and 0.23, respectively. In addition, the small molecules that could stably bind to AKT1 in compound NO.1, NO.2 and NO.3 accounted for 0.45038, 0.5254, 0.4370 and 0.59314 of the important small molecules in each compound.

[0047] 2.5 Chinese herbal compound inhibits inflammatory pathways and STAT3-related pathways: qPCR results According to Go enrichment analysis and KEGG pathway analysis, the potential disease targets of these compounds involve multiple pathways of immunity, cellular inflammation, and cell growth. In this study, the IL-6 signaling pathway, JAK-STAT signaling pathway, TNF signaling pathway, and Akt signaling pathway were selected to appear in 293T cells. Nine targets were selected: STAT3, NLRP3, JAK1, Akt, NFκB, IκB, IKK, and immune factors IL6 and TNF-α. The activation of STAT3 and JAK1 is considered to be closely related to the expression of ACE2 protein. NLRP3 is an important target protein during viral infection. 293T cells were infected with SARS-CoV-2OmicronPV (MOI=1) and cured with four traditional Chinese medicine compounds at concentrations of 500, 250, 750, and 500μg / ml, respectively. At this concentration, the relative expression levels of key genes in nine important pathways were obtained by qPCR. NO.1, NO.2 and NO.3 compounds can significantly reduce the relative expression levels of IL6, NF-kappaB and IkpaB in the inflammatory pathway, and can also inhibit the relative expression of Akt1. NO.2, NO.3 and Lianhua Qingwen capsules can significantly inhibit the proinflammatory factor TNFα. Among the four compounds, compound 1 has a good inhibitory effect on the NFK inflammatory signaling pathway. Compound NO.2 and Lianhua Qingwen can significantly inhibit the expression of JAK1 and STAT3, and can indirectly inhibit the expression of ACE2. The results are statistically significant (P < 0.05).

[0048] 2.6 Results of virus invasion into STAT3 knockout 293T cell line In the STAT3 polyclonal knockout 293T cell line, ACE2 transcription was also significantly reduced, indicating that STAT3 is indeed an activator of normal ACE2 transcription. It is worth mentioning that in this case, when ACE2 transcription was significantly inhibited, Omicron pseudovirus stimulation can still lead to a decrease in ACE2 expression in 293T cells. At this time, the inhibitory effect of the four Chinese herbal formulas on ACE2 was alleviated. In contrast, Chinese herbal compound No. 2 and Lianhua Qingwen capsule upregulated ACE2 expression. This is consistent with the trend of the effect of the four Chinese herbal compound formulas in the treatment of new coronavirus infection in the late stage of large-scale invasion. For patients with severe new coronavirus infection, intracellular ACE2 is significantly downregulated, and the ACE / ACE2 ratio is unbalanced, leading to respiratory distress and inflammation.

[0049] The serial numbers of the embodiments of the present application are only for description and do not represent the advantages and disadvantages of the embodiments. The above are only preferred embodiments of the present application, and do not limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made by using the contents of the present application specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. A method for in vitro verification of the anti-enveloped virus effect of a Chinese herbal compound, characterized in that: The specific steps include: S1. Plasmid construction: CMV-Fluc-EGFP plasmid was constructed in recipient cells using homologous recombination method; S2. Construction of pseudovirus: Using the three-plasmid system, construct pseudovirus with Fluc-EGFP dual reporter gene, and verify the infection ability and titer determination of pseudovirus through infection experiments; S3. Preparation of Chinese medicine compound: Dissolve the Chinese medicine compound in dimethyl sulfoxide and then dilute it, and prepare the medicine into different concentration gradients for later use; S4. Detect the cytotoxicity of the Chinese medicine compound by CCK-8 method to determine the safe action time and concentration; through infection inhibition experiment, co-culture the pseudovirus and the Chinese medicine compound, and observe the number of green fluorescent cells under fluorescence microscope to determine the effect of the Chinese medicine compound on the virus infection activity; S5. Explore the mechanism of the Chinese medicine compound against enveloped viruses through network pharmacology analysis and molecular docking virtual analysis methods, including exploring the key pathways and core target proteins of the compound on cells and the new coronavirus, and analyzing the potential targeting effects of the active ingredients in the compound; S6. Fluorescence quantitative PCR was used to verify the multi-target regulatory effect of the Chinese herbal compound against enveloped viruses, and to verify the targeted regulatory effect of the Chinese herbal compound on STAT3 / ACE2.

2. The method for in vitro verification of the anti-enveloped virus effect of a Chinese herbal compound according to claim 1, characterized in that: In step S1, the recipient cell is Escherichia coli Stbl3.

3. The method for in vitro verification of the anti-enveloped virus effect of a Chinese herbal compound according to claim 1, characterized in that: In step S2, the formula for titer determination is: Titer (TU / ml) = ((F×N) / (D×V))×1000 F: Average percentage of fluorescent cells (wells with a transduction rate of 10% to 15% are usually selected); N: total number of cells in each well; D: virus dilution factor; V: volume of diluted virus added to each well (μl).

4. The method for in vitro verification of the anti-enveloped virus effect of a Chinese herbal compound according to claim 1, characterized in that: Step S5 specifically includes the following sub-steps: S51. Determine the active ingredients of traditional Chinese medicine compound and their related disease targets using Herbs, TCMSP and Pubmed databases; S52. Obtain human protein-related information for all disease targets in the Uniport database, and screen disease targets associated with enveloped viruses from the Genecard database; S53, crossing the disease targets involved in the traditional Chinese medicine compound with the disease targets related to enveloped viruses to obtain a VENN diagram, and obtaining the targets of the traditional Chinese medicine compound for treating enveloped viruses; S54. Use String database and Cytoscape software to construct a PPI network, rank the targets of Chinese herbal compound for the treatment of enveloped viruses from high to low, and screen out the core targets; S55. Use David database to perform cross-gene Go enrichment analysis and KEGG pathway analysis to determine the signaling pathways involved in the treatment of enveloped viruses with traditional Chinese medicine compound; S56. Collect the crystal structures of target proteins ACE2 and Spike from the PDB database for homology modeling; S57, using AutodockVina software, intercalated natural small molecules, which are important components of traditional Chinese medicine compound; S58. Use Pymol software to analyze the results of molecular docking.

5. An application for in vitro verification of the anti-enveloped virus effect of a Chinese herbal compound, characterized in that: The method for in vitro verification of the anti-enveloped virus effect of the Chinese herbal compound as described in any one of claims 1 to 4 is used to verify the anti-SARS-CoV-2 virus effect of the Chinese herbal compound.

6. The use of a Chinese herbal compound for in vitro verification of the anti-enveloped virus effect according to claim 5, characterized in that: The Chinese medicine compound includes 30g of honeysuckle, 30g of forsythia, 15g of schizonepeta, 15g of burdock fruit, 15g of mint, 30g of platycodon, 15g of apricot, 15g of patchouli, 15g of magnolia bark, 30g of poria, 15g of pinellia, 15g of cardamom, 30g of coix seed, 30g of white hyacinth bean, 30g of charred hawthorn, 15g of jianqu, and 30g of reed root.

7. The use of a Chinese herbal compound for in vitro verification of the anti-enveloped virus effect according to claim 5, characterized in that: STAT3 is the core target of SARS-CoV-2 virus infection. The Chinese herbal compound indirectly inhibits the expression of ACE2 by inhibiting the transcription of STAT3, thereby inhibiting the recognition and invasion of the viral membrane.

Citation Information

Patent Citations

  • Small-molecule synthetic compound 1712 anti-ebola virus activity screening method

    CN109486899A

  • Anti-viral pneumonia medicine and preparation method thereof

    CN112546177A

  • Novel coronavirus pseudovirus as well as construction method and application thereof

    CN113881642A

  • Method for evaluating novel coronary pneumonia resistance of Jinlian heat clearing preparation based on network pharmacology

    CN114664459A

  • SARS-cov-2 pseudovirus mouse in-vivo packaging system and preparation method therefor

    WO2022077806A1